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OBJECTIVES: To describe noninvasive positive-pressure ventilation use in intensive care unit clinical practice, factors
associated with NPPV failure and the associated prognosis.
METHODS: A prospective cohort study.
RESULTS: Medical disorders (59%) and elective surgery (21%) were the main causes for admission to the intensive
care unit. The main indications for the initiation of noninvasive positive-pressure ventilation were the following:
post-extubation, acute respiratory failure and use as an adjunctive technique to chest physiotherapy. The
noninvasive positive-pressure ventilation failure group was older and had a higher Simplified Acute Physiology
Score II score. The noninvasive positive-pressure ventilation failure rate was 35%. The main reasons for intubation
were acute respiratory failure (55%) and a decreased level of consciousness (20%). The noninvasive positive-pressure
ventilation failure group presented a shorter period of noninvasive positive-pressure ventilation use than the
successful group [three (2-5) versus four (3-7) days]; they had lower levels of pH, HCO3 and base excess, and the FiO2
level was higher. These patients also presented lower PaO2:FiO2 ratios; on the last day of support, the inspiratory
positive airway pressure and expiratory positive airway pressure were higher. The failure group also had a longer
average duration of stay in the intensive care unit [17 (10-26) days vs. 8 (5-14) days], as well as a higher mortality rate
(9 vs. 51%). There was an association between failure and mortality, which had an odds ratio (95% CI) of 10.6 (5.93 –
19.07). The multiple logistic regression analysis using noninvasive positive pressure ventilation failure as a
dependent variable found that treatment tended to fail in patients with a Simplified Acute Physiology Score II$34,
an inspiratory positive airway pressure level$15 cmH2O and pH,7.40.
CONCLUSION: The indications for noninvasive positive-pressure ventilation were quite varied. The failure group had
a longer intensive care unit stay and higher mortality. Simplified Acute Physiology Score II$34, pH,7.40 and higher
inspiratory positive airway pressure levels were associated with failure.
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INTRODUCTION
Mechanical ventilation without the use of an invasive
artificial airway is defined as noninvasive ventilation (NIV).
Noninvasive positive-pressure ventilation (NPPV) using a
mask (or interface) that conducts gas from a positive-
pressure ventilator into the airways has become the
predominant means of administering NIV. NPPV has long
been used to treat chronic respiratory failure, but in more
recent years it has increasingly been used to treat patients
with various forms of acute respiratory failure (1). A
recently published guideline has suggested the following
guidelines: bilevel NPPV should be the first option for
patients with either a severe exacerbation of chronic
obstructive pulmonary disease (COPD) or cardiogenic
pulmonary edema; continuous positive airway pressure
delivered by mask appears to be as effective as bilevel
NPPV for patients with cardiogenic pulmonary edema;
patients with acute respiratory distress or hypoxemia, either
in the postoperative setting or in the presence of immuno-
suppression, can be considered for a trial of bilevel NPPV;
patients with COPD can be considered for a trial of early
extubation to bilevel NPPV in centers with experience in the
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use of this technique (2). All of these suggestions were based
on an extensive systematic review of published randomized
controlled trials.
Clinical NPPV experience has been reported by some
authors (3-6,9,10). This information can elucidate the
feasibility of NPPV in all of the indications mentioned in
the guidelines as well as identify any issues that arise
during clinical practice. This type of research may inform
the identification of issues related to technical or even local
characteristics that could interfere with patient outcomes.
Our aim was to describe the clinical, demographic and
technical characteristics related to noninvasive positive-
pressure ventilation (NPPV) use in clinical practice, as well
as factors associated with NPPV failure and the prognosis of
critically ill adult patients at a large university-affiliated
hospital. We then compared our findings with the current
evidence.
MATERIALS AND METHODS
The institutional ethics committee approved the study
protocol. This observational, non-interventional, prospec-
tive cohort study was performed over the course of eight
months (May - December 2007) in all consecutive adult
patients who underwent NPPV in 11 intensive care units at
a university-affiliated hospital with a total of 140 ICU beds.
Patients meeting the inclusion criteria were observed daily
until ICU discharge or death. Patients with do-not-resusci-
tate or do-not-intubate orders were excluded.
The researchers carried out the data collection through a
form specially developed for this study. These researchers
had been trained for three months before gathering the data.
The form was tested and revised during the same period.
The units were visited daily by the researchers. The
prospective data were obtained from the patient’s chart
and from the ICU staff at the moment of data collection. All
of the decisions about the use of NPPV were made by the
ICU healthcare teams. Patients whose data were incomplete
during collection were excluded from the analysis.
The variables studied were selected through review of the
relevant literature. These included the following informa-
tion: demographic data, Simplified Acute Physiology Score
(SAPS II) for the first 24 hours of ICU hospitalization (7);
NPPV features; reason for installing NPPV (COPD exacer-
bation, asthma, neuromuscular disease, acute respiratory
failure [acute lung injury or acute respiratory distress
syndrome, acute cardiogenic pulmonary edema, congestive
heart failure, pneumonia, trauma, upper airway obstruc-
tion]); post-extubation, preventive NPPV application
(defined as the use of NPPV in patients without signs of
respiratory failure with a risk of worsening, for example
during the process of fluid balance adjustment, or any
patient considered to be at risk of respiratory distress by
physicians, such as burn patients (8), or as an adjunctive
technique associated with chest physiotherapy treatment (to
assist in resolving atelectasis or airway clearance in patients
not responding to routine deep breathing exercises and
incentive spirometry)) (9-11); days of NPPV use; time
between ICU admission and NPPV initiation; time between
extubation and NPPV initiation for post-extubation NPPV;
type of equipment (CPAP-flow generator, Bipap VisionH,
Bipap ST/D-30H, ICU conventional ventilators) at the onset
and on the final day of application; NPPV parameters at the
onset and on the last day of use; type of mask (nasal, full
face, total face); arterial blood gas levels at NPPV onset and
at the time when support was discontinued; tolerance to
NPPV or the lack thereof; and NPPV-related complications
(skin lesions, gastric distension due to aerophagia, eye
irritation, vomiting, hypotension, others); cough character-
istics; the need for nasotracheal suctioning; the incidence of
nosocomial pneumonia, as clinically defined according to
the CDC (Centers for Disease Control and prevention)
criteria (12). The study end-points were the following: NIV
outcome, ICU length of stay and mortality rate. NIV success
was defined as the avoidance of orotracheal intubation and
independence from NPPV within 72 hours after its dis-
continuation, and failure was defined as a need for
intubation.
Data analysis
A descriptive analysis of the overall study population was
carried out. The quantitative variables were expressed as the
mean (standard deviation) or median (interquartile range)
when more appropriate. Categorical variables were pre-
sented as proportions. Associations between categorical
variables were analyzed with the chi-square test. Fisher’s
exact test was applied when the expected value was not
sufficient for use of the chi-square test. Continuous data
with a normal distribution were compared using Student’s
t-test; otherwise, the non-parametric equivalent was
applied. NPPV outcome was considered as the primary
endpoint. All the tests were two-tailed with a significance
level of 5% (p#0.05). Factors independently associated with
NPPV outcome were identified using a logistic regression
model. A univariate analysis was initially performed, and
all variables considered clinically relevant with a p value
less than 0.20 were included in the model. Continuous
variables (age, SAPS II score, IPAP, EPAP and pH) were
dichotomized based on the median values of the distribu-
tion. In the preliminary stage of the analysis, we studied the
possible associations between the explanatory variables
examined in this study. The goodness-of-fit was assessed
using the Hosmer-Lemeshow test. Statistical analyses were
performed with SPSSH version 16.0
RESULTS
Between May 1st and December 31st, 2007, all of the ICU
patients over 18 years old who underwent NIV treatment
were studied. During the study, 407 patients were treated
with NIV, and 392 of them were included in the analysis.
The patient characteristics are presented in Table 1. The
patient age and SAPS II score were higher in the NPPV
failure group. At the time of ICU admission, 4% of the
patients came from other hospitals, and most patients came
from the ward (41%) and emergency room (28%). Medical
disorders (59%) and elective surgery (21%) were the most
common reasons for admission. Previous ICU admissions
had occurred in 15% of the patients. The previous use of
invasive mechanical ventilation was observed in 15% of
patients, and 9% had already been treated with NPPV on
another occasion. The main indications for NPPV initiation
were the following: post-extubation, acute respiratory fail-
ure and use as an adjunct to chest physiotherapy.
The NPPV failure rate in this population was estimated to
be 35%. The main reasons for intubation (Table 1) were
acute respiratory failure (55%) and a decreased level of
consciousness (20%).
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The prevalence of smoking was 15.5% in the group in
which treatment was successful and 20.7% in the group in
which NPPV failed, but this association was not significant
(p = 0.259).
The time between ICU admission and NPPV initiation
was estimated. The overall mean (SD) time was 1.4 (2.4)
days. In the successful NPPV group, this mean (SD) period
was 1.6 (2.7) days. In the NPPV failure group, it was 1.1 (1.9)
days. This difference was not statistically significant
(p = 0.201).
The overall median (interquartile range) for the time
between extubation and NPPV initiation for post-extubation
respiratory failure cases was zero (0-1) days. No difference
was found between groups (p = 0.390).
The median (interquartile range) overall length of NPPV
use was four (2-6) days. The NPPV failure group presented
a shorter period of use than the group in which NPPV was
successful [three (2-5) versus four (3-7) days, p = 0.034,
respectively].
The data related to arterial blood gas analysis (ABG) at
the time of NPPV onset and on the last NPPV day were also
collected (Table 2). Some patients had no ABG on these
specific days. At the time of NPPV onset, 336 patients had
ABG; on the final day of NPPV, this value was 223 patients.
The PaO2/FiO2 ratio was not available in all charts, and all
recorded data are presented below. There were no differ-
ences in ABG values between the groups studied at the time
of NPPV initiation, but on the last day, the failure group
presented lower levels of pH, bicarbonate and base excess.
Patients with NPPV failure presented a lower PaO2:FiO2
ratio from the time of NPPV onset onward (Table 2).
The data related to the equipment and NPPV parameters
were compared according to outcome at NPPV onset
(Table 3) and on the last day of application (Table 4). The
full-face mask was the used the most frequently. There was
no association between the NPPV interfaces and outcome.
Initially, the CPAP flow generator was used most com-
monly for NPPV, followed by the BIPAP Vision and ICU
ventilator. At onset, the equipment used to perform NPPV
was not associated with success or failure. On the last day of
NIV use, the prevalence of CPAP flow generator use was
lower, with an increase in BIPAP VisionH use and a
reduction in the use of ICU ventilators. Patients examined
with a BIPAP Vision presented a higher NPPV failure rate.
The NPPV parameters were also analyzed according to
two sets of results collected at onset and on the last day of
NPPV application. The initial IPAP and EPAP and CPAP
levels were not associated with the NPPV outcome, but the
FiO2 levels were significantly higher in the failure group
(p= 0.006). On the last day of support, the IPAP, EPAP and
FiO2 levels were significantly higher in the NPPV failure
group (Table 3).
The rate of complications related to NPPV use was
estimated during the study. Vomiting, either associated with
aspiration or not, was the most common occurrence. There
was a significant association between the occurrence of
complications and NPPV failure. Another event associated
Table 1 - Baseline characteristics of the study group
according to the outcome of noninvasive positive-
pressure ventilation.
Characteristics
All
patients
N=392
Success
N=254
Failure
N=138
p-value,
failure vs.
success
Age, mean (SD), years 56 (20) 55 (19) 61 (16) 0.003
Male gender, n (%) 218 (56) 134 (53) 84 (61) 0.150
SAPS II, mean (SD) 36 (14) 34 (14) 38 (14) 0.010
Types of admission, n (%)
Medical 234 (60) 156 (61) 78 (57) 0.403
Elective surgery 83 (21) 47 (19) 36 (26) 0.104
Emergency surgery 74 (19) 50 (20) 24 (17) 0.675
Other* 1 (0.2) 01 (0.4) 0 (0)
Reasons for installing NPPV n (%)
Post-extubation 173 (44) 113 (45) 60 (44) 0.931
Acute respiratory failure 106 (27) 65 (26) 41 (30) 0.448
COPD* 9 (2) 7 (3) 2 (1)
Asthma* 1 (0,3) 1 (0,4) 0 (0)
Neuromuscular disease* 4 (1) 1 (0,4) 3 (2)
Other chronic respiratory
disease*
3 (1) 1 (0,4) 2 (1)
Chest physiotherapy 73 (19) 53 (21) 20 (15) 0.157
Preventive NPPV use 16 (4) 11 (4) 5 (4) 0.943
Unknown* 5 (1) 0 (0) 5 (4)
NPPV=noninvasive positive-pressure ventilation, COPD= chronic
obstructive pulmonary disease.
*not analyzed due to an insufficient number of cases.
Table 2 - Arterial blood gas analysis at NPPV onset and on
the last noninvasive positive-pressure ventilation day.
Characteristics Success Failure
p-value,
failure vs.
success
ABG at NPPV onset, n = 336 N=221 N=115
pH 7.37 (0.08) 7.37 (0.06) 0.612
PCO2 38.7 (10.3) 38.4 (10) 0.815
HCO3 23.6 (18.5) 21.9 (6.3) 0.319
Base excess - 2.5 (5.6) - 2.18 (8.1) 0.670
PaO2 /FiO2 ratio
a 283.9 (139) 226 (89) 0.034
ABG on the last day of NPPV,
n= 223
N=120 N=103
pH 7.40 (0.07) 7.35 (0.09) ,0.001
PCO2 40 (9.7) 41 (11.9) 0.536
HCO3 24.3 (6.3) 21.7 (5.5) 0.001
Base excess - 0.57 (6.7) - 3.18 (5.6) 0.002
PaO2 /FiO2 ratio
b 312 (137) 245 (123) 0.020
NPPV = noninvasive positive-pressure ventilation.
aN=97 (success 65, failure 32), b N=86 (success 44, failure 42).
Table 3 - Technical characteristics of noninvasive
ventilation: final equipment and parameters applied,
according to the noninvasive ventilation results.
Characteristics
All
patients
N=392
Success
N=254
Failure
N=138
p-value,
failure vs.
success
NPPV equipment, n (%)
CPAP- flow generator 187 (48) 130 (51) 57 (41) 0.078
BIPAP VisionH 150 (38) 87 (34) 63 (45) 0.035
BIPAP ST/D-30H 29 (7) 17 (7) 12 (9) 0.602
ICU ventilator 17 (4) 11 (4) 6 (4) 0.801
Others* 9 (2) 9 (4) 0 (0)
NPPV final parameters, median (IR)
IPAP cmH2O 14 (12-16) 14 (12-15) 14 (14-16) 0.002
EPAP cmH2O 10 (8-10) 9 (8-10) 10 (8-10) 0.001
CPAP cmH2O 10 (10-10) 10 (10-10) 10 (10-10) 0.114
FiO2 (%) 35 (30-40) 30 (25-35) 40 (35-50) ,0.001
NPPV=noninvasive positive pressure ventilation, CPAP= continuous
positive airway pressure, ICU= intensive care unit, IR = interquartile range,
IPAP= inspiratory positive airway pressure, EPAP =expiratory positive
airway pressure, FiO2= inspired oxygen fraction.
*not analyzed due to an insufficient number of cases.
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with failure was the need for nasotracheal suctioning
(Table 5).
The incidence of clinically defined nosocomial pneumo-
nia in the overall study population was 6%. There was no
difference between the groups.
The patients with NPPV failure had a higher length of
stay in the ICU when compared to the NPPV success group
[17 (10-26) days vs. 8(5-14) days]. The overall mortality rate
was 24%, and the NPPV failure group also presented a
higher mortality rate (9 vs. 51%). There was an association
between NPPV failure and mortality, with an estimated
odds ratio (95% CI) of 10.6 (5.93 – 19.07).
The multiple logistic regression analysis model using
NPPV failure as the dependent variable found that patients
with a SAPS II $ 34, IPAP level$15 cmH2O and pH,7.40
were independently associated with NPPV failure and were
kept in the final logistic model (Table 6). The goodness-of-fit
was confirmed by the Hosmer-Lemeshow test (p = 0.991).
DISCUSSION
Aside from the classic indications of NPPV use, such as
post-extubation and acute respiratory failure, we have
identified two distinct indications for NPPV: prophylactic
application and use as an adjunct to chest physiotherapy.
The prophylactic application was defined as the use of
NPPV in cases where the indication was based on clinical
criteria, such as patients who needed additional support but
did not require ventilatory support immediately, as in cases
of fluid replacement. This indication rate was only 4%.
Another indication that stood out was the use of NPPV in
association with chest physiotherapy (19%). In this case, the
objectives of positive pressure use were to assist in resolving
atelectasis and normalizing pulmonary function in patients
not responding to routine incentive spirometry and deep
breathing. The use of NPPV to assist patients in improving
ventilation and recruiting additional gas exchange units to
maintain functional residual capacity and vital capacity
with relatively little discomfort is instrumental to its success
(8). Although most epidemiological studies do not highlight
that NPPV indication, this technique is routine in our
country and is part of the procedures used in routine
hospital practice. The studies that report this type of NPPV
application were published as long as 30 years ago (9-11).
The multiple logistic regression analysis model using
NPPV failure as the dependent variable identified that
patients with IPAP levels$15 cmH2O, SAPS II$34, and
pH,7.40 were independently associated with NPPV failure.
The severity of illness, as evaluated by the SAPS II score at
the time of ICU admission, was high in our population and
independently associated with NPPV failure. Our study also
found that a SAPS II score$34 at the time of ICU admission
was independently associated with NIV failure. This finding
was similar to that reported by Antonelli et al. (23), which
recommended avoiding NPPV in ARDS patients with SAPS
II$34 due to the high levels of mortality observed in those
in whom NPPV had failed. Although our study population
was not comprised entirely of ARDS patients, we observed
that even in patients without ARDS, SAPS II$34 was
Table 4 - Events associated with NPPV use.
Events associated with NPPV use, n(%)
Total
N=392
Success
N=254
Failure
N=138
p-value,
failure vs.
success
NPPV complications 21 (5) 9 (4) 12 (9) 0.050
Complications*
Vomiting and aspiration 10 (3) 5 (2) 5 (4)
Skin lesion 3 (1) 2 (1) 1 (1)
Gastric distension 2 (1) 0 (0) 2 (1)
Arterial hypotension 1 (0) 0 (0) 1 (2)
Intolerance to NIV 69 (18) 47 (18) 22 (16) 0.619
Air leakage 8 (2) 6 (2) 2 (1) 0.718
Productive cough 109 (28) 62 (24) 47 (34) 0.055
Ineffective cough 162 (41) 108 (42) 54 (39) 0.587
Nasotracheal suctioning 115 (29) 64 (25) 51 (37) 0.020
Hypersecretion 65 (17) 36 (14) 29 (21) 0.247
Nosocomial pneumonia 22 (6) 15 (6) 7 (5) 0.910
NPPV = noninvasive positive-pressure ventilation.
*Not analyzed due to insufficient data.
Table 5 - Factors associated with noninvasive ventilation
failure – multiple logistic regression, final model.
Variables OR Lower Upper p-value
Age 1.094 0.887 1.349 0.400
EPAP 0.089 0.013 0.617 0.014
IPAP 4.452 1.529 12.968 0.006
FiO2 0.829 0.640 1.073 0.155
EPAP by FiO2 1.029 1.000 1.059 0.051
EPAP by age 1.026 1.001 1.051 0.040
Age by IPAP 0.979 0.962 0.995 0.011
OR=odds ratio, EPAP=expiratory positive airway pressure,
IPAP= inspiratory positive airway pressure, FiO2= inspired oxygen
concentration.
Table 6 - Factors associated with noninvasive ventilation
failure – multivariate analysis.
Variables OR 95% CI p-value
SAPS II,
points
,34 1.0
$34 2.97 1.31-6.99 0.010
IPAP, cm H2O
,15 1.0
$15 3.13 1.34-7.71 0.010
pH
$7.4 1.0
,7.4 2.72 1.21-6.28 0.017
OR=odds ratio, IPAP= inspiratory positive airway pressure.
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associated with treatment failure. Another study by Carlucci
et al. (14) also found that SAPS II was an independent risk
factor for secondary intubation. The authors maintain that
the SAPS II score indicates that the most severely ill patients
are poor candidates for NPPV. However, they recom-
mended that the severity score cannot be used as such on
an individual basis.
In relation to the NPPV pressure levels used, in the
multivariate analysis, the value of IPAP$15 cmH2O was
independently associated with NPPV failure. Among the
studies that evaluated NPPV parameters, only the study by
Antonelli et al. (23) reported higher IPAP values in the
failure group, but this association was not maintained in the
multivariate analysis. Other studies (6,20) did not report
such a relationship, and we observed lower levels of IPAP
and EPAP in both studies. Our findings suggest that the use
of higher values of IPAP ($15 cmH2O) indicate a higher
probability of NPPV failure.
The failure group presented lower levels of pH, bicarbonate
and base excess, and the PaCO2 did not differ between
groups. According to Rana et al. (18), the presence of
metabolic acidosis was predictive of NPPV failure, even
when shock was not present at the time NPPV was initiated.
Although patients who failed NPPV tended to have a higher
level of serum lactate, this did not reach a statistically
significant value, suggesting that not only tissue hypoperfu-
sion but alsometabolic acidosis per se, may be associatedwith
poor NPPV outcomes. Their finding are consistent our results.
We also suggest that lower levels of pHmay be a goodmarker
for a poor outcome after NPPV, as shown in Tables 2 and 6.
The overall time between extubation and NPPV initiation
for post-extubation respiratory failure cases was estimated.
Half of the patients used NPPV on the same day of
extubation, and only 25% used NPPV after the first
postoperative day. No difference was found between the
groups. We observed that clinical practice reflects the
findings of the literature, which recommends the early use
of NPPV after extubation (19-22).
The time of NPPV use in patients with failure was shorter.
This finding is similar to that reported in the literature
(13,24). Our hypothesis is that this is most likely due to the
negative impact of delayed intubation patients on the
prognosis (25).
In this unselected patient sample, we observed that the
NIV failure rate was similar to that reported in other cohort
studies (3,5). We considered the overall failure rate because
our study did not classify patients according to arterial
blood gas values. During the study period, there was no
standardized NPPV utilization protocol, and some patients
did not have arterial blood gas samples. Rather, both studies
mentioned were based on standardized protocols. The
study by Meduri et al. (5) applied a protocol in a large
group of medical patients, and Girault et al. (3) presented
two years of NIV experience at a specialized medical ICU
with 22 beds. Another study by Schettino et al. (6) reported
data related to NIV use over a period of one year at a
university-affiliated hospital. All patients submitted to NIV
at this hospital were included. The authors estimated the
rate of NIV failure in the ICU setting to be 49%. They
considered that ICU-managed patients were the sickest and
that this population was composed of patients that could
not be managed in the general ward. Patients maintained on
the ward were able to breathe spontaneously for at least one
hour. One important difference between our study and that
reported by Schettino et al. (6) is that our study population
included only a small proportion of those with chronic
respiratory disease.
The availability of a CPAP flow generator in the ICU
contributed to the frequent use of this type of equipment at
the time of NIV onset. We observed that this device was
shifted to the bilevel setting during treatment. At that time,
NIV was performed using a CPAP flow generator, Bipap
STD 30, Bipap Vision or conventional ICU ventilator. We
did not find any association with NIV outcome. A recently
published guideline by Keenan et al. (2) did not describe
any influence of the ventilatory mode or equipment on the
NIV outcome.
Univariate analysis showed that NIV was likely to fail in
patients requiring nasotracheal suctioning. This procedure
was required due to a cough that occurred in 29% of the
study population. It seems important to evaluate cough
severity, even in patients with NIV support. According to
the literature, patients with weak coughs after planned
extubation may benefit from NIV, but this procedure
requires staff with expertise in invasive airway management
(2). In a prospective multicenter survey, Carlucci et al. (14)
estimated that 52 of the 108 patients (48%) submitted to
NPPV discontinued the treatment prematurely. This was
due to an inability to manage copious secretions in 32% of
the patients. Our study estimated that 37% of the patients in
the NPPV failure group required nasotracheal suctioning.
The overall incidence of nosocomial pneumonia was 6%.
Despite differences in the diagnostic criteria, we observed a
similar rate in the literature (15). A matched case-control
study compared the rates of nosocomial infections among
patients submitted to NPPV and those submitted to invasive
mechanical ventilation. The study concluded that the use of
NPPV was associated with a lower risk of nosocomial
infections and better outcomes.
Patients with NIV failure had a poor prognosis as well as
a high mortality rate (51%). The overall mortality rate was
24%. Alsous et al. (13), in a retrospective study at a
community teaching hospital, also found a higher mortality
among those in whom BIPAP had failed. They considered
some factors that contributed to this fact: 1) a ‘‘do-not-
intubate’’ order from 7 of 18 patients, 2) less physiological
derangement among the subcohort of BIPAP success
patients, and 3) the attempt at a trial of BIPAP rather than
intubation may prolong cardiorespiratory decompensation
and worsen patient outcomes. This study concluded that
BIPAP success was associated with significantly better
outcomes (ICU length of stay and mortality). This finding
may indicate that NIV failure must be avoided through
appropriate approaches, such as staff education. Two
studies carried out at a medical ICU where there was a
protocol and a well-trained staff presented lower mortality
rates. The study by Girault et al. (3) conducted at a 22-bed
medical ICU presented an overall mortality rate of 11%; this
rate was 16% in another study by Meduri et al. (5).
An important point with respect to interpretation of our
results is that the patients were not transferred to chronic
respiratory units because this type of facility is rare in our
country. Almost all patients remain in the ICU when they
are dependent on ventilatory support. This factor may also
have affected the observed mortality rates. We consider that
educational approaches and the use of protocols can
improve NIV outcomes, as observed in the studies
mentioned above.
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The present study provides information about NIV as
part of the clinical practice at a large university-affiliated
hospital. Our intention was to analyze the main features of
this procedure in a non-controlled environment, as occurs
during a clinical trial. During the study period, there was no
standardized NIV protocol in the observed units, but we
also consider that the activities of research and teaching
may influence the results at a university-affiliated hospital.
This study presented the demographic, clinical and techni-
cal features of NPPV use in clinical practice among the
unselected ICU patients. Our results showed that patients
with NPPV failure have a poor prognosis, with a high
mortality rate and a prolonged length of stay in the ICU. The
more severe patients (higher SAPS II score and lower pH)
had higher failure rates. High levels of IPAP also indicate a
higher risk of failure. In our study, we found that
physiotherapy uses the NPPV for therapeutic purposes
and not only in cases of acute respiratory failure.
A major objective of this study is to present the main
features of the use of NPPV in patients admitted to the
intensive care unit. We understand that the study design
weakens some of our conclusions because it is an
uncontrolled study without an intervention. However, our
results are not discordant with those observed in most
previously published studies.
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